Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/23/2025

Treatment of Priapism

Diagnostic Differentiation

  • The American Urological Association recommends obtaining a corporal blood gas immediately to distinguish ischemic from non-ischemic priapism, as this determines whether you are managing a true urological emergency or a condition that can be observed 1, 2
  • Ischemic priapism is characterized by PO₂ <30 mmHg, PCO₂ >60 mmHg, pH <7.25, while non-ischemic priapism is characterized by PO₂ >90 mmHg, PCO₂ <40 mmHg, pH 7.40 1, 3

Management of Ischemic Priapism

  • The American Urological Association recommends intracavernosal phenylephrine injection with corporal aspiration as first-line treatment for ischemic priapism lasting >4 hours, regardless of underlying etiology 1, 5
  • The recommended phenylephrine concentration is 100-500 mcg/mL, with a maximum dose of 1000 mcg within the first hour 4
  • Aspiration and irrigation should accompany phenylephrine injection, with a success rate of 43-81% when combined 4, 5, 6

Management of Non-Ischemic Priapism

  • The American Urological Association recommends observation for up to 4 weeks as initial management for non-ischemic priapism, as it is not an emergency and resolves spontaneously in up to 62% of cases 7, 4
  • Selective arterial embolization using temporary absorbable materials is the treatment of choice for non-ischemic priapism that persists and requires treatment 7

Prevention of Recurrent Ischemic Priapism

  • The American Urological Association recommends PDE5 inhibitors (tadalafil or sildenafil) as first-line preventative therapy for patients with recurrent ischemic priapism, as they reduce frequency and duration with no negative side effects 5
  • Alternative preventative options include ketoconazole with prednisone, hydroxyurea (specifically for sickle cell disease patients), and home self-injection of phenylephrine on an as-needed basis 5, 4

Key Clinical Pitfalls to Avoid

  • Delaying corporal blood gas analysis can lead to delayed diagnosis and inappropriate treatment 3
  • Using exchange transfusion as primary treatment in sickle cell patients can delay effective urologic intervention by hours without proven benefit 5, 6
  • Using aspiration/sympathomimetics for non-ischemic priapism is ineffective and potentially harmful 7
  • Waiting beyond 4 hours to initiate treatment for ischemic priapism can result in smooth muscle edema and progressive irreversible damage 3
  • Failing to obtain adequate drug history can lead to missed diagnoses and inappropriate treatment 3